Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Sarcopenia Negatively Impacts Myeloma Treatment Outcomes
Sarcopenia Negatively Impacts Myeloma Treatment Outcomes
Sarcopenia negatively impacts Myeloma treatment outcomes. MM patients are generally older and may have been experiencing age-related muscle loss for years before their diagnosis of MM.
Multiple courses of treatment due to MM management can make a MM patient’s sarcopenia worse. Just exercising more might not help the MM survivor much. If you are a MM survivor who has lost muscle mass and you are considering CAR-T cell therapy, research has shown that you may have a worse outcome as a result.
The solution? Electroacupuncture plus exercise.
What is Electroacupuncture?
I am a long-term MM survivor. Experience has shown me that nutrition, supplementation, and lifestyle therapies can make a real difference in MM therapy outcomes.
If you would like to learn more about managing MM, email me at David.PeopleBeatingCancer@gmail.com with your questions. I will reply to you ASAP.
Thank you,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells
Abstract
Background Sarcopenic muscle loss has well-documented adverse impacts on treatment outcomes and mortality across cancer types and is particularly prevalent in patients with multiple myeloma, reported in 54% of newly diagnosed patients (Nandakumar ASCO 2022).
Two chimeric antigen receptor T-cell (CAR-T) constructs have been FDA approved for relapsed/refractory multiple myeloma (RRMM) after exposure to at least 4 prior lines of therapy. MM Treatment combinations frequently incorporate high dose dexamethasone, well known to cause muscle atrophy, and patients may be on therapy for many years prior to becoming eligible for commercial products with associated detrimental effects from cumulative toxicities.
We sought to determine the prevalence of sarcopenia in a real-world cohort of patients with RRMM presenting for commercial CAR-T…
Electroacupuncture Plus Exercise for Sarcopenia in Older Adults: Protocol for a Randomized, Controlled, Assessor-Blinded Trial
Background: The therapeutic effect of conventional therapies (eg, resistance training, nutritional support) for treating sarcopenia show limited efficacy in older individuals with multiple comorbidities. Therefore, this study aims to investigate whether electroacupuncture (EA) combined with standardized exercise therapy improves walking ability and other functional outcomes in older patients with sarcopenia compared to exercise-alone therapy…
Discussion: This trial will provide valuable insights into the combined use of electroacupuncture and exercise for improving walking ability and other functional outcomes in older individuals with sarcopenia. The results could potentially inform clinical practices and offer a new therapeutic option for managing sarcopenia…
Conclusion
Given the significant public health burden associated with sarcopenia, particularly in rapidly aging populations such as China and globally, identifying effective interventions represents a research priority with substantial clinical and societal implications.
This RCT will provide valuable insights into the combined use of electroacupuncture and exercise for improving walking ability and other functional outcomes in older individuals with sarcopenia. The results could potentially inform clinical practices and offer a new therapeutic option for managing sarcopenia.
If successful, this protocol could be integrated into clinical practice in various settings, such as outpatient rehabilitation centers or community health programs, offering a structured, multi-modal approach alongside nutritional counseling. Furthermore, by demonstrating clinical efficacy, this trial will lay the groundwork for future mechanistic studies designed to elucidate the biological pathways through which EA exerts its effects on muscle health.
Sarcopenia negatively impacts Myeloma treatment Sarcopenia negatively impacts Myeloma treatment